Britain’s Clinigen Group has agreed to be bought by UK-based private-equity firm Triton Investment Management in a deal that values the pharmaceutical services firm at about $1.6bn, the companies said on Wednesday.
Last week, Clinigen had confirmed advanced talks with Triton over a possible deal as pressure built up on the company on reports of activist investor Elliott Management raising its stake to propose a break up of Clinigen.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
Triton has offered 883 pence per share in cash, with shareholders also eligible to receive a previously declared final dividend of 5.46 pence per Clinigen Share, the companies said.
London-listed Clinigen helps drug developers manage clinical supplies and provides real-world data about medicines, and would be the latest addition to Triton’s burgeoning healthcare portfolio.
Source: Reuters
Can’t stop reading? Read more
Exclusive Interview: Torge Barkholtz on rethinking SME succession through operator-led investing
Exclusive Interview: Torge Barkholtz on rethinking SME succession through operator-led investing...
Rightsizing the right way
Rightsizing the right way Rightsizing an organization is never easy. But, it is a normal process...
Mozaik Investments acquires majority stake in Romania’s Genesis College, plans €30m expansion
Mozaik Investments acquires majority stake in Romania’s Genesis College, plans €30m expansion...